Serotonin News and Research

Latest Serotonin News and Research

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Priligy - new drug for premature ejaculation

For men suffering from premature ejaculation there may be a new savior in town. The new drug called Priligy is reported to triple the time a man can last in bed. It is currently not licensed in the UK, but is available and licensed for use in a number of other European countries.

28 Apr 2010

Chocolate and depression?

The ‘chocoholics’ of the world may also be the most depressed people around. A recent study found that those who were suffering from depression ate an average of 8.4 servings of chocolate a month, compared to just 5.4 servings eaten by those who were not depressed. And the people who suffered from major depression ate 11.8 servings per month.

27 Apr 2010

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

A class of antidepressants known as selective serotonin reuptake inhibitors may provide a boost to cardiovascular health by affecting the way platelets, small cells in the blood involved in clotting, clump together, say researchers at the Loyola University Medical Center in Maywood, Ill.

26 Apr 2010

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen's new TGEM(TM) Rat Models brand.

23 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

Hidden neuronal circuit that modulates sensory perception under stress identified

Did you ever wonder how you are able to perform complex tasks - even under stress? And how do emotions and memories mould your ability to live your everyday lives? The answer is just beginning to be understood and lies in hidden circuits in the brain.

19 Apr 2010

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL) in Vienna, Austria. Efficacy and safety data from the ASTUTE study are expected in the summer of 2010.

17 Apr 2010

ADHD behaviors in children associated with serotonin activity and self-blame

ADHD may be caused by alterations in the serotonin neurotransmission system combined with a tendency to experience psychosocial distress. Researchers writing in BioMed Central's open access journal Behavioral and Brain Functions found that ADHD behaviors in children and adolescents were associated with interactions between low and high serotonin activity and self-blame in relation to inter-parental conflict.

17 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Aspirin can reduce acute migraine attacks

A single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain within two hours, for more than half of people who take it. It also reduces any associated nausea, vomiting, and sensitivity to light or sound (photophobia or phonophobia).

15 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Stress and genetic factors may raise depression among medical interns

The percentage of clinicians who meet criteria for depression appears to increase significantly during medical internship, according to a report posted online that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

13 Apr 2010

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.

12 Apr 2010

Scientists discover and block pathway responsible for link between stress, anxiety and depression

Scientists at The University of Western Ontario have discovered the biological link between stress, anxiety and depression. By identifying the connecting mechanism in the brain, this high impact research led by Stephen Ferguson of Robarts Research Institute shows exactly how stress and anxiety could lead to depression.

12 Apr 2010

Concerns over safety and effectiveness of "natural" treatments for treating anxiety

In a broad-based review of studies focused on drugs that treat anxiety, a Saint Louis University doctor found no evidence supporting the use of so-called "natural" treatments in combating the effects of anxiety.

7 Apr 2010

Study: Genetic mutation in mice elevates risk of stress-induced depression

Depression and schizophrenia can be triggered by environmental stimuli and often occur in response to stressful life events. However, some people have a higher predisposition to develop these diseases, which highlights a role for genetics in determining a person's disease risk.

6 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Collegium Pharmaceutical receives USPTO notice of allowance for novel formulation of milnacipran

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Modified Release Compositions of Milnacipran", US Patent Application Number 12/211,780. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

31 Mar 2010

Serotonin News and Research

Latest Serotonin News and Research

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Priligy - new drug for premature ejaculation

Chocolate and depression?

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Hidden neuronal circuit that modulates sensory perception under stress identified

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

ADHD behaviors in children associated with serotonin activity and self-blame

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Aspirin can reduce acute migraine attacks

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Stress and genetic factors may raise depression among medical interns

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

Scientists discover and block pathway responsible for link between stress, anxiety and depression

Concerns over safety and effectiveness of "natural" treatments for treating anxiety

Study: Genetic mutation in mice elevates risk of stress-induced depression

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Collegium Pharmaceutical receives USPTO notice of allowance for novel formulation of milnacipran

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Serotonin News and Research

Latest Serotonin News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in